ScholarLens Back to search
1985•PubMedRequires access

Results obtained with the NIVGRIP inactivated influenza vaccine applicable by nasal and/or oral route.

A L Petrescu, N Cajal

Open publisher page 2 citations

Abstract

The NIVGRIP inactivated influenza vaccine prepared in the "Stefan S. Nicolau" Institute of Virology has proved its efficacy in the specific prophylaxis of influenza. The vaccine can be administered by nasal and/or oral route and has a very low reactogenicity. Application of the NIVGRIP vaccine results in seroconversion rates of 50-70% and in rises in the levels of local neutralizing antibodies in 75-80% of the vaccines. Numerous epidemiological surveys have ascertained that the protection rate obtained by nasal administration of the NIVGRIP vaccine ranges from 50 to 90%, being comparable with that of other commercially available vaccines. The advantages of the use of an inactivated, whole virus vaccine applicable by nonparenteral routes are discussed.

About this research paper

What this paper is about

The NIVGRIP inactivated influenza vaccine prepared in the "Stefan S. Nicolau" Institute of Virology has proved its efficacy in the specific prophylaxis of influenza. The vaccine can be administered by nasal and/or oral route and has a very low reactogenicity. Application of the NIVGRIP vaccine results in seroconversion rates of 50-70% and in rises in the levels of local neutralizing antibodies in 75-80% of the vaccines. Numerous epidemiological surveys have ascertained that the protection rate obtained by nasal administration of the NIVGRIP vaccine ranges from 50 to 90%, being comparable with that of other commercially available vaccines. The advantages of the use of an inactivated, whole virus vaccine applicable by nonparenteral routes are discussed.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The NIVGRIP inactivated influenza vaccine prepared in the "Stefan S. Nicolau" Institute of Virology has proved its efficacy in the specific prophylaxis of influenza. The vaccine can be administered by nasal and/or oral route and has a very low reactogenicity. Application of the NIVGRIP vaccine results in seroconversion rates of 50-70% and in rises in the levels of local neutralizing antibodies in 75-80% of the vaccines. Numerous epidemiological surveys have ascertained that the protection rate obtained by nasal administration of the NIVGRIP vaccine ranges from 50 to 90%, being comparable with that of other commercially available vaccines. The advantages of the use of an inactivated, whole virus vaccine applicable by nonparenteral routes are discussed.

Key concepts: Reactogenicity, Seroconversion, Influenza vaccine, Medicine, Virology, Nasal administration, Live attenuated influenza vaccine, Virus

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Results obtained with the NIVGRIP inactivated influenza vaccine applicable by nasal and/or oral route. — Research Paper | ScholarLens